Molecular Imaging

Alzheimer’s could be diagnosed earlier if the blood-brain barrier was monitored as a biomarker and potential drug target using MRI or PET, according to research published online Sept. 24 in Nature Neuroscience.

BlueCross BlueShield of Tennessee announced it will expand Medicare coverage for cardiac PET, according to the Society for Nuclear Medicine and Molecular Imaging (SNMMI). The change will take effect later this year.

In patients with diagnosed Alzheimer’s disease (AD), [18F] flortaucipir PET imaging proved accurate in distinguishing AD from other neurodegenerative diseases, according to a multicenter study published in JAMA.

Amyloid load (AβL) imaged in vivo using [18F]Florbetapir PET is a more sensitive biomarker for measuring the global amyloid (Aβ) burden compared to composite standardized uptake value ratio (SUVr), reported authors of a Sept. 6 Journal of Nuclear Medicine study.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) recently submitted comment to BlueCross BlueShield (BCBS) of Tennessee supporting its proposed expansion of cardiac PET coverage.

Authors of a recent Journal of Nuclear Medicine study have discovered potential for misdiagnosis when relying solely on prostate-specific membrane antigen (PSMA) PET imaging in prostate cancer staging.

Researchers from the Salk Institute in San Diego and the University of Florida have used cryo-electron microscopy (cryo-EM) imaging to analyze a 3D model of the AAV2 virus. The advanced molecular imaging technique may demonstrate the potential for the virus to act as a delivery vehicle for gene therapies, according to research published Sept. 7 in Nature Communications.

A German-led research team has developed a new nuclear medicine imaging technique that outperforms standard tumor imaging by targeting cancer-associated fibroblasts (CAFs), according to research published in the September issue of the Journal of Nuclear Medicine.

Using patient-specific body weight-based protocols during whole-body fluorodeoxyglucose (18F-FDG) PET/CT can greatly reduce radiation dosage while maintaining image quality, according to authors of an Academic Radiology study.

For patients with Alzheimer’s disease, amyloid PET imaging can improve diagnosis, diagnostic confidence and treatment, according to a JAMA Neurology study. The method is beneficial whether results are positive or negative.

Aetna announced, Thursday, Aug. 16, it will expand its coverage of the PET tracer gallium-68 (Ga-68) dotatate, according to a Society of Nuclear Medicine and Molecular Imaging (SNMMI) release. The radiopharmaceutical is now considered “medically necessary.”

Extending PET acquisition time during PET/MRI for rectal cancer staging increases identified lymph nodes and has no impact on scan time, reported authors of a recent American Journal of Roentgenology study.